SEC Comment Letter 0000000000-24-014126 to Bodhi Tree Biotechnology Inc (CIK 0002041531) (BDTB)
Bodhi Tree Biotechnology Inc (CIK 0002041531)
Date: Dec. 20, 2024 · CIK: 0002041531 · Accession: 0000000000-24-014126
AI Filing Summary & Sentiment
Letter
December 20, 2024 Xiaohang Wang Chief Executive Officer Bodhi Tree Biotechnology Inc 4125 Blackhawk Plaza Circle, Suite 172 Danville, CA 94506 Re:Bodhi Tree Biotechnology Inc Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted December 16, 2024 CIK No. 0002041531 Dear Xiaohang Wang: We have reviewed your amended registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Unless we note otherwise, any references to prior comments are to comments in our December 5, 2024 letter. Amendment No. 2 to Draft Registration Statement on Form S-1 Description of Business, page 21 1.We note your response to prior comment 2 and reissue in part. Please revise your disclosure to clearly state, if true, that you are not currently subject to any governmental regulations. General 2.We note your response to prior comment 7 and reissue. Please revise to address the costs and time constraints associated with effecting service of legal process, enforcing foreign judgments or bringing actions in China against you or your management.
December 20, 2024 Page 2 Please contact Nasreen Mohammed at 202-551-3773 or Joel Parker at 202-551-3651 if you have questions regarding comments on the financial statements and related matters. Please contact Michael Purcell at 202-551-5351 or Liz Packebusch at 202-551-8749 with any other questions. Sincerely, Division of Corporation Finance Office of Trade & Services cc:Cassi Olson
Show Raw Text
December 20, 2024
Xiaohang Wang
Chief Executive Officer
Bodhi Tree Biotechnology Inc
4125 Blackhawk Plaza Circle, Suite 172
Danville, CA 94506
Re:Bodhi Tree Biotechnology Inc
Amendment No. 2 to Draft Registration Statement on Form S-1
Submitted December 16, 2024
CIK No. 0002041531
Dear Xiaohang Wang:
We have reviewed your amended registration statement and have the following
comments.
Please respond to this letter by amending your registration statement and providing
the requested information. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information
you provide in response to this letter, we may have additional comments. Unless we note
otherwise, any references to prior comments are to comments in our December 5, 2024 letter.
Amendment No. 2 to Draft Registration Statement on Form S-1
Description of Business, page 21
1.We note your response to prior comment 2 and reissue in part. Please revise your
disclosure to clearly state, if true, that you are not currently subject to any
governmental regulations.
General
2.We note your response to prior comment 7 and reissue. Please revise to address the
costs and time constraints associated with effecting service of legal process, enforcing
foreign judgments or bringing actions in China against you or your management.
December 20, 2024
Page 2
Please contact Nasreen Mohammed at 202-551-3773 or Joel Parker at 202-551-3651
if you have questions regarding comments on the financial statements and related
matters. Please contact Michael Purcell at 202-551-5351 or Liz Packebusch at 202-551-8749
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services
cc:Cassi Olson